Medtech firm Invizius, which specialises in using technology to aid dialysis patients, has been named ‘Best Innovative MedTech company’ at the OBN Awards.

The award follows a seed investment of £500,000 from Mercia Fund Managers in May 2018.

The company’s product, H-Guard, acts as a primer that ‘hides’ the blood filter used in dialysis from the body’s immune system. This has the potential to cut the risks of cardiovascular disease, which severely reduces life expectancy among long-term dialysis patients.

Richard Boyd, chief executive officer of Invizius, said: “The team is enormously proud that our innovation has been recognised with this prestigious award. The company is on an exciting journey and this adds to our momentum.”

Invizius suggest there is potential to use the technology with other devices or procedures such as cardiopulmonary bypass, catheters, stents, organ transplants and vascular grafts.